Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Debt to Equity (2019 - 2025)

Historic Debt to Equity for Puma Biotechnology (PBYI) over the last 7 years, with Q3 2025 value amounting to $0.29.

  • Puma Biotechnology's Debt to Equity fell 7336.75% to $0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.29, marking a year-over-year decrease of 7336.75%. This contributed to the annual value of $0.73 for FY2024, which is 6097.1% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Debt to Equity is $0.29, which was down 7336.75% from $0.43 recorded in Q2 2025.
  • Puma Biotechnology's Debt to Equity's 5-year high stood at $13.63 during Q1 2022, with a 5-year trough of -$39.69 in Q4 2021.
  • For the 5-year period, Puma Biotechnology's Debt to Equity averaged around $0.36, with its median value being $1.96 (2024).
  • The largest annual percentage gain for Puma Biotechnology's Debt to Equity in the last 5 years was 45664.89% (2021), contrasted with its biggest fall of 14027.85% (2021).
  • Puma Biotechnology's Debt to Equity (Quarter) stood at -$39.69 in 2021, then surged by 111.46% to $4.55 in 2022, then crashed by 59.01% to $1.86 in 2023, then tumbled by 60.97% to $0.73 in 2024, then crashed by 59.81% to $0.29 in 2025.
  • Its Debt to Equity was $0.29 in Q3 2025, compared to $0.43 in Q2 2025 and $0.58 in Q1 2025.